Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses recent advancements in understanding the use of 5 alpha-reductase inhibitors for benign prostatic hyperplasia, indicating that dual isoenzyme inhibitors like dutasteride may enhance treatment outcomes, but no new clinical results are presented.

This review found that 5α-reductase inhibitors (such as finasteride and dutasteride) effectively reduce prostate size and stabilize hair loss but are associated with sexual dysfunction; they remain essential treatments for BPH and androgenic alopecia, requiring tailored risk-benefit assessments.

This study reported that while no effective treatment exists for frontal fibrosing alopecia, oral 5-alpha-reductase inhibitors showed the most promise, inducing a good clinical response in 45% of patients.

Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.

Finasteride may help treat frontal fibrosing alopecia, but more research is needed.

This review discusses the rationale for targeting 5α-reductase isoenzymes in prostate cancer prevention and treatment, highlighting the potential benefits of using inhibitors like dutasteride and finasteride but reports no new experimental results.

This study found that androgen metabolism within hair follicles varies significantly between compartments, with dermal papillae showing high 5α-reductase activity, suggesting a key role in androgen-driven hair growth responses.

This report details a rare case of favus in Japan, identifying Trichophyton schoenleinii in a 63-year-old woman through DNA sequencing, who was successfully treated with oral terbinafine and topical luliconazole.

This synthesis report details the successful development of a C-14 labeled isotopomer of LY300502, a 5α-reductase inhibitor, through a multi-step radiochemical process.

This review discusses how 5α-reductase inhibitors affect PSA levels in benign prostatic hyperplasia treatment and their role in prostate cancer screening, but reports no new clinical findings.

This review analyzed clinical trials and guidelines on 5-α-reductase inhibitors (5-ARIs) and found these drugs significantly improve urinary symptoms in BPH and stabilize hair loss in androgenic alopecia, but may cause sexual dysfunction and gynecomastia.

This study found that a novel topical dutasteride lotion, FOL100, demonstrated excellent safety, tolerability, and usability with promising signs of clinical benefit for mild-to-moderate male pattern baldness.

This commentary notes that 5-alpha reductase inhibitors have successfully treated benign prostatic hyperplasia and androgenetic alopecia but reports no new findings.

This report from a consensus meeting concluded that while 5-alpha reductase inhibitors are beneficial for BPH treatment and prostate cancer risk reduction, their role in clinical practice should be more widely integrated into prostate management guidelines.

In this in-vitro study, researchers identified finasteride as the most effective FDA-approved drug for expanding functional myeloid-derived suppressor cells, suggesting its potential future use in immunosuppressive therapies.

This study found that Litfulo improved hair regrowth in patients aged 12 and older with severe alopecia areata but did not meaningfully improve anxiety or depression symptoms compared to placebo.

This study found that the highest rebound value in concrete with high volume slag occurs with 40% slag content, 10–20 mm basalt aggregates, and greater carbonation depth.

NUL-5 may boost hair growth by improving hair follicle health and structure.

In this pilot study, finasteride increased testosterone/dihydrotestosterone and progesterone/dihydroprogesterone ratios in normal ovulatory women but did not alter ovulation or gonadotropin secretion.

This meta-analysis reported that the use of 5α-reductase inhibitors significantly increased the risk of postfinasteride syndrome-like adverse effects in men treated for benign prostatic hyperplasia or androgenetic alopecia.

This study reports an improved and more cost-effective 7-step synthesis method for finasteride with an overall yield of 20.01%.

This study found that a bleach bath treatment with 0.005% HOCI reduced the expression of certain serine proteases in cultured keratinocytes and lowered skin pH in atopic dermatitis patients, potentially improving symptoms by modulating the NF-kB pathway.

In this study, the authors concluded that there is no clear difference in suicidal ideation between different 5α-reductase inhibitors, but results vary by finasteride dose, patient age, and psychiatric history.

This review discusses biochemical studies on 5 alpha-reductase and its inhibitors, comparing IC50 and Ki values for various compounds, but reports no new experimental results.

This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.